News

First Sublingual Immunotherapy Tablet for House Dust Mite Allergic Rhinitis May Be US-bound

Author and Disclosure Information

 

AT 2016 AAAAI ANNUAL MEETING

References

Merck already has two FDA-approved SLIT tablets developed with ALK on the U.S. market: Grastek, for treatment of grass pollen–induced allergic rhinitis in children and adults, and Ragwitek, for ragweed-induced allergic disease in adults.

The trial was sponsored by Merck and presented by a full-time company employee.

Pages

Recommended Reading

Rash, Reaction, or Red Flag?
Clinician Reviews
Mechanism for Dust mite–triggered Atopic Dermatitis Identified
Clinician Reviews
Early-wheezing Patterns Prefigure Adolescent Respiratory Outcomes and Asthma
Clinician Reviews
Recent Active Asthma Raises AAA Rupture Risk
Clinician Reviews
ACIP Recommends LAIV as an Option for All People With Egg Allergies
Clinician Reviews
AAAAI: EpiPen Jr Needles Too Long for Many Children Under 15 kg
Clinician Reviews
AAAAI: Early Peanut Consumption Brings Lasting Protection From Allergy
Clinician Reviews
No Evidence Supports Hydrolyzed Formula Over Cows’ Milk for Allergy Prevention
Clinician Reviews
Even Small Food Doses Maintain Tolerance in Pediatric Oral Immunotherapy
Clinician Reviews
Even Small Food Doses Maintain Tolerance in Pediatric Oral Immunotherapy
Clinician Reviews